Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sridhar Mani

Showing results (111-120 of 170) with videos related to

Pageof 17
Sort By:
Scientific Reports|August 24, 2016
Pregnane X Receptor Regulates Pathogen-Induced Inflammation and Host Defense against an Intracellular Bacterial Infection through Toll-like Receptor 4Zhijuan Qiu, Jorge L Cervantes, Basak B Cicek, et al.
International Journal of Molecular Sciences|April 15, 2020
Gut Microbial Catabolites of Tryptophan Are Ligands and Agonists of the Aryl Hydrocarbon Receptor: A Detailed CharacterizationBarbora Vyhlídalová, Kristýna Krasulová, Petra Pečinková, et al.
Cellular and Molecular Gastroenterology and Hepatology|October 29, 2022
The Pregnane X Receptor and Indole-3-Propionic Acid Shape the Intestinal Mesenchyme to Restrain Inflammation and FibrosisKyle L Flannigan, Kristoff M Nieves, Holly E Szczepanski, et al.
Bioorganic Chemistry|February 14, 2025
Decoding structural determinants of aryl hydrocarbon receptor antagonism by monoterpenoidsIveta Zůvalová, Barbora Vyhlídalová, Karolína Ondrová, et al.
Investigational New Drugs|January 2, 2007
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancersSanjay Goel, Kavita Desai, Sirisha Karri, et al.
American Journal of Clinical Oncology|October 24, 2002
Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignanciesSanjay Goel, Minaxi Jhawer, Lakshmi Rajdev, et al.
Pediatric Research|January 24, 2018
Targeting the PXR-TLR4 signaling pathway to reduce intestinal inflammation in an experimental model of necrotizing enterocolitisKezhen Huang, Subhajit Mukherjee, Vera DesMarais, et al.
American Journal of Clinical Oncology|December 4, 2004
A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinomaCathy Eng, Ramesh K Ramanathan, Ramesh K Ramathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumorsSridhar Mani, Hayley McDaid, Anne Hamilton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignanciesKyriakos P Papadopoulos, Sanjay Goel, Murali Beeram, et al.
Pageof 17

Showing results (111-120 of 170) with videos related to

Sort By:
Pageof 17
Scientific Reports|August 24, 2016
Pregnane X Receptor Regulates Pathogen-Induced Inflammation and Host Defense against an Intracellular Bacterial Infection through Toll-like Receptor 4Zhijuan Qiu, Jorge L Cervantes, Basak B Cicek, et al.
International Journal of Molecular Sciences|April 15, 2020
Gut Microbial Catabolites of Tryptophan Are Ligands and Agonists of the Aryl Hydrocarbon Receptor: A Detailed CharacterizationBarbora Vyhlídalová, Kristýna Krasulová, Petra Pečinková, et al.
Cellular and Molecular Gastroenterology and Hepatology|October 29, 2022
The Pregnane X Receptor and Indole-3-Propionic Acid Shape the Intestinal Mesenchyme to Restrain Inflammation and FibrosisKyle L Flannigan, Kristoff M Nieves, Holly E Szczepanski, et al.
Bioorganic Chemistry|February 14, 2025
Decoding structural determinants of aryl hydrocarbon receptor antagonism by monoterpenoidsIveta Zůvalová, Barbora Vyhlídalová, Karolína Ondrová, et al.
Investigational New Drugs|January 2, 2007
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancersSanjay Goel, Kavita Desai, Sirisha Karri, et al.
American Journal of Clinical Oncology|October 24, 2002
Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignanciesSanjay Goel, Minaxi Jhawer, Lakshmi Rajdev, et al.
Pediatric Research|January 24, 2018
Targeting the PXR-TLR4 signaling pathway to reduce intestinal inflammation in an experimental model of necrotizing enterocolitisKezhen Huang, Subhajit Mukherjee, Vera DesMarais, et al.
American Journal of Clinical Oncology|December 4, 2004
A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinomaCathy Eng, Ramesh K Ramanathan, Ramesh K Ramathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumorsSridhar Mani, Hayley McDaid, Anne Hamilton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignanciesKyriakos P Papadopoulos, Sanjay Goel, Murali Beeram, et al.
Pageof 17